VorapaxarSulfate , ≥98% , 705260-08-8

CAS NO.：705260-08-8

Empirical Formula: C29H35FN2O8S

Molecular Weight: 590.66

MDL number: MFCD16038877

PRODUCT Properties

• storage temp.: 4°C, away from moisture
• solubility: DMSO : 125 mg/mL (211.63 mM; Need ultrasonic)| (insoluble)
• form: Solid
• color: White to off-white
• Water Solubility: Water : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)

Description and Uses

Merck Sharp & Dohme successfully obtained approval in the EU in 2014 for vorapaxar sulfate, marketed as Zontivity®. The drug is a first-in-class thrombin receptor (also referred to as a protease-activated or PAR-1) antagonist which, when used in conjunction with antiplatelet therapy, has been shown to reduce the chance of myocardial infarction and stroke, particularly in patients with a history of cardiac events. Antagonism of PAR-1 allows for thrombin-mediated fibrin deposition while blocking thrombinmediated platelet activation.

SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis. acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H320-H335
• Precautionary statements: P261-P280-P301+P312-P302+P352-P305+P351+P338